NCT01694160View on ClinicalTrials.gov

Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria

PHASE3CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

December 31, 2015

Conditions
Proteinuria
Interventions
DRUG

Paricalcitol

Zemplar (paricalcitol) 2ug daily, oral intake

Trial Locations (1)

0424

Renal Section, Oslo University Hospital, Rikshospitalet, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT01694160 - Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria | Biotech Hunter | Biotech Hunter